Micafungin
drugOn this page
Also known as MicafunginaMicafungine
Summary
Micafungin (CHEMBL457547) is an approved small-molecule antiinfective agent (ATC J02AX05); indicated across 9 conditions including candidemia and candidiasis, invasive.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: J02AX05
- Indications: 9 conditions
- Clinical trials: 50
- Chemistry: 1270.3 Da · C56H71N9O23S
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL457547 |
| Name | Micafungin |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 477468 |
| ChEBI | CHEBI:600520 |
| ATC | J02AX05 |
| Molecular formula | C56H71N9O23S |
| Molecular weight | 1270.3 |
| InChIKey | PIEUQSKUWLMALL-YABMTYFHSA-N |
SMILES: CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)[C@@H](CC(=O)N)O)C)O)O)O
IUPAC name: [5-[(1S,2S)-2-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-3-[(1R)-3-amino-1-hydroxy-3-oxopropyl]-11,20,21,25-tetrahydroxy-15-[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-18-[[4-[5-(4-pentoxyphenyl)-1,2-oxazol-3-yl]benzoyl]amino]-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-6-yl]-1,2-dihydroxyethyl]-2-hydroxyphenyl] hydrogen sulfate
ChEBI definition: A cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-β-D-glucan, an integral component of the fungal cell wall. It is used as the sodium salt for the treatment of invasive candidiasis, and of aspergillosis in patients who are intolerant of other therapy.
Pharmacological roles (ChEBI): antiinfective agent.
Also known as: Micafungin, Micafungina, Micafungine, micafungin, MICAFUNGIN
Parent form; salt/anhydrous children: CHEMBL1237070
Patent coverage: 74 distinct patent families (120 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 119 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 12 (assay-derived). Sample: Estrogen receptor, Thromboxane A2 receptor, Progesterone receptor, Muscarinic acetylcholine receptor M1, Sodium-dependent noradrenaline transporter, Mu-type opioid receptor, Sodium-dependent dopamine transporter, 3’,5’-cyclic-AMP phosphodiesterase 4A, Adenosine receptor A3, NEDD8-conjugating enzyme Ubc12.
Bioactivity
ChEMBL activities: 5 potent at pChembl ≥ 5 of 12 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| PGR | 5.41 | AC50 | 3868 | nM | CHEMBL_ACT_25204184 |
| TBXA2R | 5.15 | AC50 | 7116 | nM | CHEMBL_ACT_25197752 |
| ESR1 | 5.14 | AC50 | 7246 | nM | CHEMBL_ACT_25138751 |
| OPRM1 | 5.11 | AC50 | 7683 | nM | CHEMBL_ACT_25158068 |
| CHRM1 | 5.04 | AC50 | 9052 | nM | CHEMBL_ACT_25210121 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
9 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| candidemia | 3 | MONDO:0044070 | EFO:1001282 |
| candidiasis, invasive | 3 | MONDO:0044067 | EFO:1001283 |
| oral candidiasis | 3 | MONDO:0005886 | EFO:0007406 |
| candidiasis | 3 | MONDO:0002026 | MONDO:0002026 |
| fungal infectious disease | 3 | MONDO:0002041 | MONDO:0002041 |
| aspergillosis | 2 | MONDO:0005657 | EFO:0007157 |
| leukemia | 2 | MONDO:0005059 | EFO:0000565 |
| graft versus host disease | 1 | MONDO:0013730 | MONDO:0013730 |
| neoplasm | 1 | MONDO:0005070 | MONDO:0004992 |
Clinical trials
Total trials: 50.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 16 |
| PHASE3 | 11 |
| PHASE2 | 10 |
| PHASE1 | 8 |
| Not specified | 4 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00304772 | PHASE4 | WITHDRAWN | Fluconazole Versus Micafungin for Candida Bloodstream Infection in Non-Neutropenic Patients |
| NCT00423163 | PHASE4 | WITHDRAWN | A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis |
| NCT00839540 | PHASE4 | COMPLETED | Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins |
| NCT01090141 | PHASE4 | COMPLETED | Drug Concentration Analysis of Micafungin in Overweight, Obese, and Extremely Obese Volunteers |
| NCT01135589 | PHASE4 | UNKNOWN | Micafungin Prevention Study for Fungal Disease in Child Receiving Allogenic Hematopoietic Stem Cell Transplantation |
| NCT01200355 | PHASE4 | COMPLETED | Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome |
| NCT01982071 | PHASE4 | TERMINATED | A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia |
| NCT02164890 | PHASE4 | COMPLETED | Pharmacokinetics of Micafungin in Patients of Intensive Care Units |
| NCT02646774 | PHASE4 | TERMINATED | Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive Aspergillosis |
| NCT02646800 | PHASE4 | TERMINATED | Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp |
| NCT02651038 | PHASE4 | COMPLETED | Pharmacokinetics of Micafungin During Continuous Venovenous Hemofiltration |
| NCT03102658 | PHASE4 | COMPLETED | Micafungin Pharmacokinetics in Obese Patients |
| NCT03906916 | PHASE4 | TERMINATED | Comparison of Two Diagnostic Tests in Patients With Suspected Invasive Candidiasis in Internal Medicine Wards and Who Are Currently Timely Treated With Micafungin |
| NCT05496725 | PHASE4 | COMPLETED | Evaluate Bioequivalence of Micafungin (50mg/Vial) |
| NCT05784844 | PHASE4 | WITHDRAWN | Antimicrobial Revision in Persistent Febrile Neutropenia |
| NCT06413056 | PHASE4 | COMPLETED | Micafungin Versus Amphotercine B in Treatment of Invasive Fungal Infection |
| NCT00048750 | PHASE3 | TERMINATED | Comparative Study of Micafungin (FK463) Versus Placebo as Prophylactic Antifungal Therapy in the ICU |
| NCT00105144 | PHASE3 | COMPLETED | Study of Micafungin in Patients With Invasive Candidiasis or Candidemia |
| NCT00106288 | PHASE3 | COMPLETED | Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia |
| NCT00189709 | PHASE3 | COMPLETED | Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia |
| NCT00665639 | PHASE3 | COMPLETED | Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis |
| NCT00666185 | PHASE3 | COMPLETED | Comparative Trial of Micafungin Versus Fluconazole for Treating Esophageal Candidiasis |
| NCT00794703 | PHASE3 | COMPLETED | A Study to Compare Efficacy and Safety of Mycamine® and Itraconazole for Preventing Fungal Infections |
| NCT00815516 | PHASE3 | TERMINATED | Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis |
| NCT01058174 | PHASE3 | COMPLETED | Liver Transplant European Study Into the Prevention of Fungal Infection |
| NCT01773876 | PHASE3 | COMPLETED | Empirical Antifungal Treatment in ICUS |
| NCT01974375 | PHASE3 | UNKNOWN | Micafungin Versus Fluconazole for Prevention of Invasive Fungal Disease in Living Donor Liver Transplant Recipients |
| NCT02145832 | PHASE2/PHASE3 | COMPLETED | Fluconazole Versus Micafungin in Neonates With Candidiasis |
| NCT00047827 | PHASE2 | TERMINATED | Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis |
| NCT00376337 | PHASE2 | TERMINATED | Micafungin Salvage Mono-therapy in Invasive Aspergillosis |
| NCT01122368 | PHASE2 | COMPLETED | A Study to Evaluate Pre-emptive Treatment for Invasive Candidiasis in High Risk Surgical Subjects |
| NCT01207128 | PHASE2 | WITHDRAWN | Trial of Combination Antifungal Therapy (Vori+Mica vs. Vori+Placebo) in Invasive Aspergillosis |
| NCT01417169 | PHASE2 | UNKNOWN | Micafungin Prevention Study for Invasive Fungal Disease in Pediatric & Adolescent Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation |
| NCT01888458 | PHASE2 | COMPLETED | Antifungal Prophylaxis With Micafungin After Cord Blood Allogeneic Stem Cell Transplantation (MycaCOORD) |
| NCT02172768 | PHASE2 | COMPLETED | Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease |
| NCT02244606 | PHASE2 | COMPLETED | Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis |
| NCT02440178 | PHASE2 | COMPLETED | Micafungin Prophylaxis During 1st Induction Chemotherapy for De Novo Acute Leukemia |
| NCT03421002 | PHASE2 | COMPLETED | Determination of Levels of Micafungin in Neonates Suffering From Systemic Candidiasis and/or Candida Meningitis |
| NCT00606268 | PHASE1 | COMPLETED | A Study of Safety and Pharmacokinetics of Repeated Dose of Micafungin as Antifungal Prophylaxis in Children and Adolescents Who Undergo Hematopoietic Stem Cell Transplant |
| NCT00607763 | PHASE1 | COMPLETED | Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).